Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 19Kidney Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 5von Hippel-Lindau Disease 4Neoplasm Metastasis 2Recurrence 1Pheochromocytoma 1Paraganglioma 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Glioblastoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

belzutifan 4Everolimus 2vatalanib 1spartalizumab 1palbociclib 1lenvatinib 1cabozantinib 1PT2385 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × von Hippel-Lindau Disease × belzutifan × Clear all
NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

Withdrawn

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡